查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
憩室炎疾病市场份额,规模,趋势,行业分析报告,按类型,按疗法,按最终用户,按地区,按细分市场,预测，2023-2032 年
市场调查报告书
商品编码
1287681

憩室炎疾病市场份额,规模,趋势,行业分析报告,按类型,按疗法,按最终用户,按地区,按细分市场,预测，2023-2032 年

Diverticulitis Disease Market Share, Size, Trends, Industry Analysis Report, By Type (Uncomplicated, Complicated); By Treatment; By End-User; By Region; Segment Forecast, 2023-2032
出版日期: | 出版商: Polaris Market Research | 英文 115 Pages | 商品交期: 最快1-2个工作天内

价格

根据 Polaris 市场研究的一项新研究，到 2032 年，全球憩室炎疾病市场预计将达到 38.6 亿美元。 该报告深入探讨了当前市场动态，并对未来市场增长进行了分析。

老年人口的增长将导致患者数量的增加并扩大憩室病的市场。 因此，预计全球市场将需要用于改善治疗的药物。 对最先进医疗保健的需求不断增长,吸烟率上升以及年轻人向久坐生活方式的转变是主要驱动力。 例如，根据CDC 2022年报告，西弗吉尼亚州的吸烟率高达23.8%，为美国最高。 吸烟是可预防疾病的主要原因，仅在美国就造成大量死亡，吸烟每年导致近 500,000 480,000 人死亡。 但CDC预测，到2020年，将有3080万美国人，即12.5%的成年人吸烟。

大肠憩室病或憩室病在世界范围内变得越来越常见。 儘管大多数患者在很长一段时间内没有症状，但大肠憩室病，特别是急性憩室炎，相当常见，并开始给国家医疗保健系统带来重大的经济负担。 例如，根据亚历山大霍金斯 (Alexander T. Hawkins) 在 2022 年发表的一篇研究论文，60 岁以上的人中约有 33% 患有乙状结肠憩室病，据说在发达国家更为常见。 多达 15% 的患者可能在一生中的某个阶段患上憩室炎。

目前，重点是测试多种治疗方式并确定最佳治疗策略。 然而不幸的是，仍然缺乏可靠的数据来支持药物治疗预防急性憩室炎復发的功效。 在这里，我们简要描述这些治疗的疗效和未来前景。

憩室炎市场报告亮点

  • 2022年，“无并发症”将主宰市场，主宰市场。 市场扩大的主要原因是抗生素治疗研究的不断进步。
  • 到 2022 年，药物疗法将主导市场。 该类别受益于使用抗生素治疗急性憩室炎引起的感染，这是市场增长的关键驱动力。
  • 到 2022 年，医院将占据市场中最大的收入部分。 市场增长的关键驱动力是医院中有专家可以指导患者选择合适的测试。
  • 到 2022 年，北美将占全球收入的大部分。 在预测期内，预计市场将受益于老年人口不断增长和人们对当地健康问题意识不断增强等因素。
  • 在全球开展业务的公司包括 Sucampo Pharmaceuticals,Valeant Pharmaceuticals International,Synergy Pharmaceuticals,Ardelyx,Astellas Pharma,Novartis AG,Hikma Pharmaceuticals 和 Baxter International。

内容

第一章简介

第 2 章执行摘要

第三章研究方法

第 4 章全球憩室炎疾病市场洞察

  • 憩室炎疾病市场 - 最终用户概况
  • 憩室炎疾病市场动态
    • 驱动因素和机遇
      • 对久坐生活方式的适应能力增强，胃肠道显着生长
      • 口服药物的需求不断增长
    • 制约因素和问题
      • 成本高
  • PESTEL 分析
  • 憩室炎疾病市场的最终用户趋势
  • 价值链分析
  • COVID-19 的影响分析

第 5 章全球憩室炎疾病市场（按类型）

  • 主要发现
  • 简介
  • 并不復杂
  • 复杂

第 6 章全球憩室炎疾病市场（按治疗）

  • 主要发现
  • 简介
  • 医学
  • 手术
  • 支持性护理
  • 青霉素类抗生素
  • 抗生素
  • 膳食补充剂
  • 点滴输液

第 7 章全球憩室炎疾病市场（按最终用户）

  • 主要发现
  • 简介
  • 专业中心
  • 医院
  • 研究中心

第 8 章全球憩室炎疾病市场（按地区）

  • 主要发现
  • 简介
    • 2019-2032 年憩室炎疾病市场评估（按地区）
  • 憩室炎疾病市场 - 北美
    • 北美：2019-2032 年憩室炎疾病市场（按类型）
    • 北美：憩室炎疾病市场，按最终用户划分，2019-2032 年
    • 北美：憩室炎疾病市场（按治疗方法），2019-2032 年
    • 憩室炎疾病市场 - 美国
    • 憩室炎疾病市场 - 加拿大
  • 憩室炎疾病市场 - 欧洲
    • 欧洲：2019-2032 年憩室炎疾病市场（按类型）
    • 欧洲：憩室炎疾病市场（按最终用户），2019-2032 年
    • 欧洲：2019-2032 年憩室炎治疗市场
    • 憩室炎疾病市场 - 英国
    • 憩室炎疾病市场 - 法国
    • 憩室炎疾病市场 - 德国
    • 憩室炎疾病市场 - 意大利
    • 憩室炎疾病市场 - 西班牙
    • 憩室炎疾病市场 - 荷兰
    • 憩室炎疾病市场 - 俄罗斯
  • 憩室炎疾病市场 - 亚太地区
    • 亚太地区：2019-2032 年憩室炎疾病市场（按类型）
    • 亚太地区：憩室炎疾病市场（按最终用户），2019-2032 年
    • 亚太地区：憩室炎疾病市场（按治疗方法），2019-2032 年
    • 憩室炎疾病市场 - 中国
    • 憩室炎疾病市场 - 印度
    • 憩室炎疾病市场 - 马来西亚
    • 憩室炎疾病市场 - 日本
    • 憩室炎疾病市场 - 印度尼西亚
    • 憩室炎疾病市场 - 韩国
  • 憩室炎疾病市场 - 中东和非洲
    • 中东和非洲：2019-2032 年憩室炎疾病市场（按类型）
    • 中东和非洲：2019-2032 年最终用户憩室炎疾病市场
    • 中东和非洲：2019-2032 年憩室炎疾病治疗市场
    • 憩室炎疾病市场 - 沙特阿拉伯
    • 憩室炎疾病市场 - 阿联酋
    • 憩室炎疾病市场 - 以色列
    • 憩室炎疾病市场 - 南非
  • 憩室炎疾病市场 - 拉丁美洲
    • 拉丁美洲：2019-2032 年憩室炎疾病市场（按类型）
    • 拉丁美洲：憩室炎疾病市场，按最终用户划分，2019-2032 年
    • 拉丁美洲：憩室炎疾病市场（按治疗方法），2019-2032 年
    • 憩室炎疾病市场 - 墨西哥
    • 憩室炎疾病市场 - 巴西
    • 憩室炎疾病市场 - 阿根廷

第 9 章竞争格局

  • 扩张和收购分析
    • 扩展名
    • 收购
  • 伙伴关係/协作/协议/披露

第 10 章公司简介

  • Pfizer
  • G.D. Searle
  • Teva Pharmaceutical
  • Abbott Laboratories
  • Braun Medical
  • GSK
  • Bayer HealthCare
  • Roche Holding
  • Johnson and Johnson
  • Sucampo Pharmaceuticals
  • Valeant Pharmaceuticals
  • Synergy Pharmaceuticals
  • Ardelyx
  • Astellas Pharma
  • Novartis
  • Hikma Pharmaceuticals
  • Baxter International
Product Code: PM3168

The global diverticulitis disease market size is expected to reach USD 3.86 billion by 2032, according to a new study by Polaris market research. The report "Diverticular Disease Market Share, Size, Trends, Industry Analysis Report, By Type (Uncomplicated, Complicated); By Treatment; By End-User; By Region; Segment Forecast, 2023-2032" gives a detailed insight into current market dynamics and provides analysis on future market growth.

Rise in the elderly population causes a rise in the patient population, which in turn increases the market for diverticular illness. The worldwide market has therefore forecast the demand for medications for improved treatment. It has been primarily fueled by the rising demand for cutting-edge medical care, the rise in cigarette smoking, and the broad movement of young people toward sedentary lifestyles. For instance, West Virginia had the highest smoking rate in the United States in 2022, with a rate of 23.8%, according to the CDC's 2022 report. The leading cause of the preventable disease & recorded substantial deaths in the U.S alone, smoking accounts for almost 500,000 480,000 deaths annually. However, the CDC predicted that 30.8 million Americans or 12.5% of adults smoked cigarettes in 2020.

Diverticulosis and diverticular disease of the colon are becoming more common worldwide. Despite the fact that the majority of patients stay asymptomatic for a very long time, diverticular illness of the colon, particularly acute diverticulitis, is quite common and is beginning to put a large financial strain on national health systems. For instance, a research paper by Alexander T. Hawkins, published in 2022, states that diverticulosis of the sigmoid colon affects about 33% of people over the age of 60 and is frequent in the industrialized world. Diverticulitis could occur in up to 15% of these patients at some time in their lives.

The current emphasis is on determining the best therapy strategy through the testing of numerous treatments. Unfortunately, there is still a lack of solid data supporting the efficacy of a medicinal approach to preventing a recurrence of acute diverticulitis. Here, we give a succinct overview of these treatments' efficacy and prospects for the future.

Diverticular Disease Market Report Highlights

  • Uncomplicated will dominate the market in 2022, accounting for major sales. The primary reason for the market's expansion is the ongoing advancement in antibiotic treatment research.
  • In 2022, medications will rule the market. Since the primary element driving market growth is the use of antibiotics to treat infections that may arise in acute diverticulitis, the category benefits from this.
  • In 2022, hospitals made up the greatest revenue portion of the market. The key driver of market growth is the presence of experts in hospitals who can guide patients in selecting appropriate tests.
  • North America will produce majority of global income in 2022. Over the course of the forecast period, the market is predicted to gain from elements including the growing senior population and expanding public awareness of local health issues.
  • The global players with global presence include Sucampo Pharmaceuticals, Valeant Pharmaceuticals International, Synergy Pharmaceuticals, Ardelyx, Astellas Pharma, Novartis AG, Hikma Pharmaceuticals and Baxter International.

Polaris Market Research has segmented the Diverticular Disease Market report based on type, treatment, end-user and region:

Diverticular Disease, Type Outlook (Revenue - USD Billion, 2019 - 2032)

  • Uncomplicated
  • Complicated

Diverticular Disease, Treatment Outlook (Revenue - USD Billion, 2019 - 2032)

  • Medications
  • Surgery
  • Supportive care
  • Penicillin Antibiotic
  • Antibiotics
  • Dietary Supplements
  • IV fluids

Diverticular Disease, End-User Outlook (Revenue - USD Billion, 2019 - 2032)

  • Specialty centers
  • Hospitals
  • Research centers

Diverticular Disease, Regional Outlook (Revenue - USD Billion, 2019 - 2032)

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Netherlands
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Indonesia
  • Malaysia
  • Latin America
  • Argentina
  • Brazil
  • Mexico
  • Middle East & Africa
  • UAE
  • Saudi Arabia
  • Israel
  • South Africa

Table of Contents

1. Introduction

  • 1.1. Report Description
    • 1.1.1. Objectives of the Study
    • 1.1.2. Market Scope
    • 1.1.3. Assumptions
  • 1.2. Stakeholders

2. Executive Summary

  • 2.1. Market Highlights

3. Research Methodology

  • 3.1. Overview
    • 3.1.1. Data Mining
  • 3.2. Data Sources
    • 3.2.1. Primary Sources
    • 3.2.2. Secondary Sources

4. Global Diverticulitis Disease Market Insights

  • 4.1. Diverticulitis Disease Market - End-User Snapshot
  • 4.2. Diverticulitis Disease Market Dynamics
    • 4.2.1. Drivers and Opportunities
      • 4.2.1.1. Increased sedentary lifestyle adaptation and significant gastrointestinal growth
      • 4.2.1.2. Rising Demand for Oral Drugs
    • 4.2.2. Restraints and Challenges
      • 4.2.2.1. High cost
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers (Moderate)
    • 4.3.2. Threats of New Entrants: (Low)
    • 4.3.3. Bargaining Power of Buyers (Moderate)
    • 4.3.4. Threat of Substitute (Moderate)
    • 4.3.5. Rivalry among existing firms (High)
  • 4.4. PESTEL Analysis
  • 4.5. Diverticulitis Disease Market End-User Trends
  • 4.6. Value Chain Analysis
  • 4.7. COVID-19 Impact Analysis

5. Global Diverticulitis Disease Market, by Type

  • 5.1. Key Findings
  • 5.2. Introduction
    • 5.2.1. Global Diverticulitis Disease Market, by Type, 2019-2032 (USD Billion)
  • 5.3. Uncomplicated
    • 5.3.1. Global Diverticulitis Disease Market, by Uncomplicated, by Region, 2019-2032 (USD Billion)
  • 5.4. Complicated
    • 5.4.1. Global Diverticulitis Disease Market, by Complicated, by Region, 2019-2032 (USD Billion)

6. Global Diverticulitis Disease Market, by Treatment

  • 6.1. Key Findings
  • 6.2. Introduction
    • 6.2.1. Global Diverticulitis Disease Market, by Treatment, 2019-2032 (USD Billion)
  • 6.3. Medications
    • 6.3.1. Global Diverticulitis Disease Market, by Medications, by Region, 2019-2032 (USD Billion)
  • 6.4. Surgery
    • 6.4.1. Global Diverticulitis Disease Market, by Surgery, by Region, 2019-2032 (USD Billion)
  • 6.5. Supportive care
    • 6.5.1. Global Diverticulitis Disease Market, by Supportive care, by Region, 2019-2032 (USD Billion)
  • 6.6. Penicillin Antibiotic
    • 6.6.1. Global Diverticulitis Disease Market, by Penicillin Antibiotic, by Region, 2019-2032 (USD Billion)
  • 6.7. Antibiotics
    • 6.7.1. Global Diverticulitis Disease Market, by Antibiotics, by Region, 2019-2032 (USD Billion)
  • 6.8. Dietary Supplements
    • 6.8.1. Global Diverticulitis Disease Market, by Dietary Supplements, by Region, 2019-2032 (USD Billion)
  • 6.9. IV fluids
    • 6.9.1. Global Diverticulitis Disease Market, by IV fluids, by Region, 2019-2032 (USD Billion)

7. Global Diverticulitis Disease Market, by End-User

  • 7.1. Key Findings
  • 7.2. Introduction
    • 7.2.1. Global Diverticulitis Disease Market, by End-User, 2019-2032 (USD Billion)
  • 7.3. Specialty centres
    • 7.3.1. Global Diverticulitis Disease Market, by Specialty centres, By Region, 2019-2032 (USD Billion)
  • 7.4. Hospitals
    • 7.4.1. Global Diverticulitis Disease Market, by Hospitals, By Region, 2019-2032 (USD Billion)
  • 7.5. Research centres
    • 7.5.1. Global Diverticulitis Disease Market, by Research centres, By Region, 2019-2032 (USD Billion)

8. Global Diverticulitis Disease Market, by Geography

  • 8.1. Key findings
  • 8.2. Introduction
    • 8.2.1. Diverticulitis Disease Market Assessment, By Geography, 2019-2032 (USD Billion)
  • 8.3. Diverticulitis Disease Market - North America
    • 8.3.1. North America: Diverticulitis Disease Market, by Type, 2019-2032 (USD Billion)
    • 8.3.2. North America: Diverticulitis Disease Market, by End-User, 2019-2032 (USD Billion)
    • 8.3.3. North America: Diverticulitis Disease Market, by Treatment, 2019-2032 (USD Billion)
    • 8.3.4. Diverticulitis Disease Market - U.S.
      • 8.3.4.1. U.S.: Diverticulitis Disease Market, by Type, 2019-2032 (USD Billion)
      • 8.3.4.2. U.S.: Diverticulitis Disease Market, by End-User, 2019-2032 (USD Billion)
      • 8.3.4.3. U.S.: Diverticulitis Disease Market, by Treatment, 2019-2032 (USD Billion)
    • 8.3.5. Diverticulitis Disease Market - Canada
      • 8.3.5.1. Canada: Diverticulitis Disease Market, by Type, 2019-2032 (USD Billion)
      • 8.3.5.2. Canada.: Diverticulitis Disease Market, by End-User, 2019-2032 (USD Billion)
      • 8.3.5.3. Canada: Diverticulitis Disease Market, by Treatment, 2019-2032 (USD Billion)
  • 8.4. Diverticulitis Disease Market - Europe
    • 8.4.1. Europe: Diverticulitis Disease Market, by Type, 2019-2032 (USD Billion)
    • 8.4.2. Europe.: Diverticulitis Disease Market, by End-User, 2019-2032 (USD Billion)
    • 8.4.3. Europe: Diverticulitis Disease Market, by Treatment, 2019-2032 (USD Billion)
    • 8.4.4. Diverticulitis Disease Market - UK
      • 8.4.4.1. UK: Diverticulitis Disease Market, by Type, 2019-2032 (USD Billion)
      • 8.4.4.2. UK.: Diverticulitis Disease Market, by End-User, 2019-2032 (USD Billion)
      • 8.4.4.3. UK: Diverticulitis Disease Market, by Treatment, 2019-2032 (USD Billion)
    • 8.4.5. Diverticulitis Disease Market - France
      • 8.4.5.1. France: Diverticulitis Disease Market, by Type, 2019-2032 (USD Billion)
      • 8.4.5.2. France.: Diverticulitis Disease Market, by End-User, 2019-2032 (USD Billion)
      • 8.4.5.3. France: Diverticulitis Disease Market, by Treatment, 2019-2032 (USD Billion)
    • 8.4.6. Diverticulitis Disease Market - Germany
      • 8.4.6.1. Germany: Diverticulitis Disease Market, by Type, 2019-2032 (USD Billion)
      • 8.4.6.2. Germany.: Diverticulitis Disease Market, by End-User, 2019-2032 (USD Billion)
      • 8.4.6.3. Germany: Diverticulitis Disease Market, by Treatment, 2019-2032 (USD Billion)
    • 8.4.7. Diverticulitis Disease Market - Italy
      • 8.4.7.1. Italy: Diverticulitis Disease Market, by Type, 2019-2032 (USD Billion)
      • 8.4.7.2. Italy.: Diverticulitis Disease Market, by End-User, 2019-2032 (USD Billion)
      • 8.4.7.3. Italy: Diverticulitis Disease Market, by Treatment, 2019-2032 (USD Billion)
    • 8.4.8. Diverticulitis Disease Market - Spain
      • 8.4.8.1. Spain: Diverticulitis Disease Market, by Type, 2019-2032 (USD Billion)
      • 8.4.8.2. Spain.: Diverticulitis Disease Market, by End-User, 2019-2032 (USD Billion)
      • 8.4.8.3. Spain: Diverticulitis Disease Market, by Treatment, 2019-2032 (USD Billion)
    • 8.4.9. Diverticulitis Disease Market - Netherlands
      • 8.4.9.1. Netherlands: Diverticulitis Disease Market, by Type, 2019-2032 (USD Billion)
      • 8.4.9.2. Netherlands.: Diverticulitis Disease Market, by End-User, 2019-2032 (USD Billion)
      • 8.4.9.3. Netherlands: Diverticulitis Disease Market, by Treatment, 2019-2032 (USD Billion)
    • 8.4.10. Diverticulitis Disease Market - Russia
      • 8.4.10.1. Russia: Diverticulitis Disease Market, by Type, 2019-2032 (USD Billion)
      • 8.4.10.2. Russia.: Diverticulitis Disease Market, by End-User, 2019-2032 (USD Billion)
      • 8.4.10.3. Russia: Diverticulitis Disease Market, by Treatment, 2019-2032 (USD Billion)
  • 8.5. Diverticulitis Disease Market - Asia Pacific
    • 8.5.1. Asia Pacific: Diverticulitis Disease Market, by Type, 2019-2032 (USD Billion)
    • 8.5.2. Asia Pacific.: Diverticulitis Disease Market, by End-User, 2019-2032 (USD Billion)
    • 8.5.3. Asia Pacific: Diverticulitis Disease Market, by Treatment, 2019-2032 (USD Billion)
    • 8.5.4. Diverticulitis Disease Market - China
      • 8.5.4.1. China: Diverticulitis Disease Market, by Type, 2019-2032 (USD Billion)
      • 8.5.4.2. China.: Diverticulitis Disease Market, by End-User, 2019-2032 (USD Billion)
      • 8.5.4.3. China: Diverticulitis Disease Market, by Treatment, 2019-2032 (USD Billion)
    • 8.5.5. Diverticulitis Disease Market - India
      • 8.5.5.1. India: Diverticulitis Disease Market, by Type, 2019-2032 (USD Billion)
      • 8.5.5.2. India.: Diverticulitis Disease Market, by End-User, 2019-2032 (USD Billion)
      • 8.5.5.3. India: Diverticulitis Disease Market, by Treatment, 2019-2032 (USD Billion)
    • 8.5.6. Diverticulitis Disease Market - Malaysia
      • 8.5.6.1. Malaysia: Diverticulitis Disease Market, by Type, 2019-2032 (USD Billion)
      • 8.5.6.2. Malaysia.: Diverticulitis Disease Market, by End-User, 2019-2032 (USD Billion)
      • 8.5.6.3. Malaysia: Diverticulitis Disease Market, by Treatment, 2019-2032 (USD Billion)
    • 8.5.7. Diverticulitis Disease Market - Japan
      • 8.5.7.1. Japan: Diverticulitis Disease Market, by Type, 2019-2032 (USD Billion)
      • 8.5.7.2. Japan.: Diverticulitis Disease Market, by End-User, 2019-2032 (USD Billion)
      • 8.5.7.3. Japan: Diverticulitis Disease Market, by Treatment, 2019-2032 (USD Billion)
    • 8.5.8. Diverticulitis Disease Market - Indonesia
      • 8.5.8.1. Indonesia: Diverticulitis Disease Market, by Type, 2019-2032 (USD Billion)
      • 8.5.8.2. Indonesia.: Diverticulitis Disease Market, by End-User, 2019-2032 (USD Billion)
      • 8.5.8.3. Indonesia: Diverticulitis Disease Market, by Treatment, 2019-2032 (USD Billion)
    • 8.5.9. Diverticulitis Disease Market - South Korea
      • 8.5.9.1. South Korea: Diverticulitis Disease Market, by Type, 2019-2032 (USD Billion)
      • 8.5.9.2. South Korea.: Diverticulitis Disease Market, by End-User, 2019-2032 (USD Billion)
      • 8.5.9.3. South Korea: Diverticulitis Disease Market, by Treatment, 2019-2032 (USD Billion)
  • 8.6. Diverticulitis Disease Market - Middle East & Africa
    • 8.6.1. Middle East & Africa: Diverticulitis Disease Market, by Type, 2019-2032 (USD Billion)
    • 8.6.2. Middle East & Africa.: Diverticulitis Disease Market, by End-User, 2019-2032 (USD Billion)
    • 8.6.3. Middle East & Africa: Diverticulitis Disease Market, by Treatment, 2019-2032 (USD Billion)
    • 8.6.4. Diverticulitis Disease Market - Saudi Arabia
      • 8.6.4.1. Saudi Arabia: Diverticulitis Disease Market, by Type, 2019-2032 (USD Billion)
      • 8.6.4.2. Saudi Arabia.: Diverticulitis Disease Market, by End-User, 2019-2032 (USD Billion)
      • 8.6.4.3. Saudi Arabia: Diverticulitis Disease Market, by Treatment, 2019-2032 (USD Billion)
    • 8.6.5. Diverticulitis Disease Market - UAE
      • 8.6.5.1. UAE: Diverticulitis Disease Market, by Type, 2019-2032 (USD Billion)
      • 8.6.5.2. UAE.: Diverticulitis Disease Market, by End-User, 2019-2032 (USD Billion)
      • 8.6.5.3. UAE: Diverticulitis Disease Market, by Treatment, 2019-2032 (USD Billion)
    • 8.6.6. Diverticulitis Disease Market - Israel
      • 8.6.6.1. Israel: Diverticulitis Disease Market, by Type, 2019-2032 (USD Billion)
      • 8.6.6.2. Israel.: Diverticulitis Disease Market, by End-User, 2019-2032 (USD Billion)
      • 8.6.6.3. Israel: Diverticulitis Disease Market, by Treatment, 2019-2032 (USD Billion)
    • 8.6.7. Diverticulitis Disease Market - South Africa
      • 8.6.7.1. South Africa: Diverticulitis Disease Market, by Type, 2019-2032 (USD Billion)
      • 8.6.7.2. South Africa.: Diverticulitis Disease Market, by End-User, 2019-2032 (USD Billion)
      • 8.6.7.3. South Africa: Diverticulitis Disease Market, by Treatment, 2019-2032 (USD Billion)
  • 8.7. Diverticulitis Disease Market - Latin America
    • 8.7.1. Latin America: Diverticulitis Disease Market, by Type, 2019-2032 (USD Billion)
    • 8.7.2. Latin America.: Diverticulitis Disease Market, by End-User, 2019-2032 (USD Billion)
    • 8.7.3. Latin America: Diverticulitis Disease Market, by Treatment, 2019-2032 (USD Billion)
    • 8.7.4. Diverticulitis Disease Market - Mexico
      • 8.7.4.1. Mexico: Diverticulitis Disease Market, by Type, 2019-2032 (USD Billion)
      • 8.7.4.2. Mexico.: Diverticulitis Disease Market, by End-User, 2019-2032 (USD Billion)
      • 8.7.4.3. Mexico: Diverticulitis Disease Market, by Treatment, 2019-2032 (USD Billion)
    • 8.7.5. Diverticulitis Disease Market - Brazil
      • 8.7.5.1. Brazil: Diverticulitis Disease Market, by Type, 2019-2032 (USD Billion)
      • 8.7.5.2. Brazil.: Diverticulitis Disease Market, by End-User, 2019-2032 (USD Billion)
      • 8.7.5.3. Brazil: Diverticulitis Disease Market, by Treatment, 2019-2032 (USD Billion)
    • 8.7.6. Diverticulitis Disease Market - Argentina
      • 8.7.6.1. Argentina: Diverticulitis Disease Market, by Type, 2019-2032 (USD Billion)
      • 8.7.6.2. Argentina.: Diverticulitis Disease Market, by End-User, 2019-2032 (USD Billion)
      • 8.7.6.3. Argentina: Diverticulitis Disease Market, by Treatment, 2019-2032 (USD Billion)

9. Competitive Landscape

  • 9.1. Expansion and Acquisition Analysis
    • 9.1.1. Expansion
    • 9.1.2. Acquisitions
  • 9.2. Partnerships/Collaborations/Agreements/Exhibitions

10. Company Profiles

  • 10.1. Pfizer
    • 10.1.1. Company Overview
    • 10.1.2. Financial PerTreatmentance
    • 10.1.3. Treatment Benchmarking
    • 10.1.4. Recent Development
  • 10.2. G.D. Searle
    • 10.2.1. Company Overview
    • 10.2.2. Financial PerTreatmentance
    • 10.2.3. Treatment Benchmarking
    • 10.2.4. Recent Development
  • 10.3. Teva Pharmaceutical
    • 10.3.1. Company Overview
    • 10.3.2. Financial PerTreatmentance
    • 10.3.3. Treatment Benchmarking
    • 10.3.4. Recent Development
  • 10.4. Abbott Laboratories
    • 10.4.1. Company Overview
    • 10.4.2. Financial PerTreatmentance
    • 10.4.3. Treatment Benchmarking
    • 10.4.4. Recent Development
  • 10.5. Braun Medical
    • 10.5.1. Company Overview
    • 10.5.2. Financial PerTreatmentance
    • 10.5.3. Treatment Benchmarking
    • 10.5.4. Recent Development
  • 10.6. GSK
    • 10.6.1. Company Overview
    • 10.6.2. Financial PerTreatmentance
    • 10.6.3. Treatment Benchmarking
    • 10.6.4. Recent Development
  • 10.7. Bayer HealthCare
    • 10.7.1. Company Overview
    • 10.7.2. Financial PerTreatmentance
    • 10.7.3. Treatment Benchmarking
    • 10.7.4. Recent Development
  • 10.8. Roche Holding
    • 10.8.1. Company Overview
    • 10.8.2. Financial PerTreatmentance
    • 10.8.3. Treatment Benchmarking
    • 10.8.4. Recent Development
  • 10.9. Johnson and Johnson
    • 10.9.1. Company Overview
    • 10.9.2. Financial PerTreatmentance
    • 10.9.3. Treatment Benchmarking
    • 10.9.4. Recent Development
  • 10.10. Sucampo Pharmaceuticals
    • 10.10.1. Company Overview
    • 10.10.2. Financial PerTreatmentance
    • 10.10.3. Treatment Benchmarking
    • 10.10.4. Recent Development
  • 10.11. Valeant Pharmaceuticals
    • 10.11.1. Company Overview
    • 10.11.2. Financial PerTreatmentance
    • 10.11.3. Treatment Benchmarking
    • 10.11.4. Recent Development
  • 10.12. Synergy Pharmaceuticals
    • 10.12.1. Company Overview
    • 10.12.2. Financial PerTreatmentance
    • 10.12.3. Treatment Benchmarking
    • 10.12.4. Recent Development
  • 10.13. Ardelyx
    • 10.13.1. Company Overview
    • 10.13.2. Financial PerTreatmentance
    • 10.13.3. Treatment Benchmarking
    • 10.13.4. Recent Development
  • 10.14. Astellas Pharma
    • 10.14.1. Company Overview
    • 10.14.2. Financial PerTreatmentance
    • 10.14.3. Treatment Benchmarking
    • 10.14.4. Recent Development
  • 10.15. Novartis
    • 10.15.1. Company Overview
    • 10.15.2. Financial PerTreatmentance
    • 10.15.3. Treatment Benchmarking
    • 10.15.4. Recent Development
  • 10.16. Hikma Pharmaceuticals
    • 10.16.1. Company Overview
    • 10.16.2. Financial PerTreatmentance
    • 10.16.3. Treatment Benchmarking
    • 10.16.4. Recent Development
  • 10.17. Baxter International
    • 10.17.1. Company Overview
    • 10.17.2. Financial PerTreatmentance
    • 10.17.3. Treatment Benchmarking
    • 10.17.4. Recent Development

List of Tables

  • Table 1 Global Diverticulitis Disease Market, by Type, 2019-2032 (USD Billion)
  • Table 2 Global Diverticulitis Disease Market, by Treatment, 2019-2032 (USD Billion)
  • Table 3 Global Diverticulitis Disease Market, by End-User, 2019-2032 (USD Billion)
  • Table 4 Diverticulitis Disease Market Assessment, By Geography, 2019-2032 (USD Billion)
  • Table 5 North America: Diverticulitis Disease Market, by Type, 2019-2032 (USD Billion)
  • Table 6 North America: Diverticulitis Disease Market, by Treatment, 2019-2032 (USD Billion)
  • Table 7 North America: Diverticulitis Disease Market, by End-User, 2019-2032 (USD Billion)
  • Table 8 U.S.: Diverticulitis Disease Market, by Type, 2019-2032 (USD Billion)
  • Table 9 U.S.: Diverticulitis Disease Market, by Treatment, 2019-2032 (USD Billion)
  • Table 10 U.S.: Diverticulitis Disease Market, by End-User, 2019-2032 (USD Billion)
  • Table 11 Canada: Diverticulitis Disease Market, by Type, 2019-2032 (USD Billion)
  • Table 12 Canada: Diverticulitis Disease Market, by Treatment, 2019-2032 (USD Billion)
  • Table 13 Canada: Diverticulitis Disease Market, by End-User, 2019-2032 (USD Billion)
  • Table 14 Europe: Diverticulitis Disease Market, by Type, 2019-2032 (USD Billion)
  • Table 15 Europe: Diverticulitis Disease Market, by Treatment, 2019-2032 (USD Billion)
  • Table 16 Europe: Diverticulitis Disease Market, by End-User, 2019-2032 (USD Billion)
  • Table 17 UK: Diverticulitis Disease Market, by Type, 2019-2032 (USD Billion)
  • Table 18 UK: Diverticulitis Disease Market, by Treatment, 2019-2032 (USD Billion)
  • Table 19 UK: Diverticulitis Disease Market, by End-User, 2019-2032 (USD Billion)
  • Table 20 France: Diverticulitis Disease Market, by Type, 2019-2032 (USD Billion)
  • Table 21 France: Diverticulitis Disease Market, by Treatment, 2019-2032 (USD Billion)
  • Table 22 France: Diverticulitis Disease Market, by End-User, 2019-2032 (USD Billion)
  • Table 23 Germany: Diverticulitis Disease Market, by Type, 2019-2032 (USD Billion)
  • Table 24 Germany: Diverticulitis Disease Market, by Treatment, 2019-2032 (USD Billion)
  • Table 25 Germany: Diverticulitis Disease Market, by End-User, 2019-2032 (USD Billion)
  • Table 26 Italy: Diverticulitis Disease Market, by Type, 2019-2032 (USD Billion)
  • Table 27 Italy: Diverticulitis Disease Market, by Treatment, 2019-2032 (USD Billion)
  • Table 28 Italy: Diverticulitis Disease Market, by End-User, 2019-2032 (USD Billion)
  • Table 29 Spain: Diverticulitis Disease Market, by Type, 2019-2032 (USD Billion)
  • Table 30 Spain: Diverticulitis Disease Market, by Treatment, 2019-2032 (USD Billion)
  • Table 31 Spain: Diverticulitis Disease Market, by End-User, 2019-2032 (USD Billion)
  • Table 32 Netherlands: Diverticulitis Disease Market, by Type, 2019-2032 (USD Billion)
  • Table 33 Netherlands: Diverticulitis Disease Market, by Treatment, 2019-2032 (USD Billion)
  • Table 34 Netherlands: Diverticulitis Disease Market, by End-User, 2019-2032 (USD Billion)
  • Table 35 Russia: Diverticulitis Disease Market, by Type, 2019-2032 (USD Billion)
  • Table 36 Russia: Diverticulitis Disease Market, by Treatment, 2019-2032 (USD Billion)
  • Table 37 Russia: Diverticulitis Disease Market, by End-User, 2019-2032 (USD Billion)
  • Table 38 Asia Pacific: Diverticulitis Disease Market, by Type, 2019-2032 (USD Billion)
  • Table 39 Asia Pacific: Diverticulitis Disease Market, by Treatment, 2019-2032 (USD Billion)
  • Table 40 Asia Pacific: Diverticulitis Disease Market, by End-User, 2019-2032 (USD Billion)
  • Table 41 China: Diverticulitis Disease Market, by Type, 2019-2032 (USD Billion)
  • Table 42 China: Diverticulitis Disease Market, by Treatment, 2019-2032 (USD Billion)
  • Table 43 China: Diverticulitis Disease Market, by End-User, 2019-2032 (USD Billion)
  • Table 44 India: Diverticulitis Disease Market, by Type, 2019-2032 (USD Billion)
  • Table 45 India: Diverticulitis Disease Market, by Treatment, 2019-2032 (USD Billion)
  • Table 46 India: Diverticulitis Disease Market, by End-User, 2019-2032 (USD Billion)
  • Table 47 Malaysia: Diverticulitis Disease Market, by Type, 2019-2032 (USD Billion)
  • Table 48 Malaysia: Diverticulitis Disease Market, by Treatment, 2019-2032 (USD Billion)
  • Table 49 Malaysia: Diverticulitis Disease Market, by End-User, 2019-2032 (USD Billion)
  • Table 50 Japan: Diverticulitis Disease Market, by Type, 2019-2032 (USD Billion)
  • Table 51 Japan: Diverticulitis Disease Market, by Treatment, 2019-2032 (USD Billion)
  • Table 52 Japan: Diverticulitis Disease Market, by End-User, 2019-2032 (USD Billion)
  • Table 53 Indonesia: Diverticulitis Disease Market, by Type, 2019-2032 (USD Billion)
  • Table 54 Indonesia: Diverticulitis Disease Market, by Treatment, 2019-2032 (USD Billion)
  • Table 55 Indonesia: Diverticulitis Disease Market, by End-User, 2019-2032 (USD Billion)
  • Table 56 South Korea: Diverticulitis Disease Market, by Type, 2019-2032 (USD Billion)
  • Table 57 South Korea: Diverticulitis Disease Market, by Treatment, 2019-2032 (USD Billion)
  • Table 58 South Korea: Diverticulitis Disease Market, by End-User, 2019-2032 (USD Billion)
  • Table 59 Middle East & Africa: Diverticulitis Disease Market, by Type, 2019-2032 (USD Billion)
  • Table 60 Middle East & Africa: Diverticulitis Disease Market, by Treatment, 2019-2032 (USD Billion)
  • Table 61 Middle East & Africa: Diverticulitis Disease Market, by End-User, 2019-2032 (USD Billion)
  • Table 62 Saudi Arabia: Diverticulitis Disease Market, by Type, 2019-2032 (USD Billion)
  • Table 63 Saudi Arabia: Diverticulitis Disease Market, by Treatment, 2019-2032 (USD Billion)
  • Table 64 Saudi Arabia: Diverticulitis Disease Market, by End-User, 2019-2032 (USD Billion)
  • Table 65 UAE: Diverticulitis Disease Market, by Type, 2019-2032 (USD Billion)
  • Table 66 UAE: Diverticulitis Disease Market, by Treatment, 2019-2032 (USD Billion)
  • Table 67 UAE: Diverticulitis Disease Market, by End-User, 2019-2032 (USD Billion)
  • Table 68 Israel: Diverticulitis Disease Market, by Type, 2019-2032 (USD Billion)
  • Table 69 Israel: Diverticulitis Disease Market, by Treatment, 2019-2032 (USD Billion)
  • Table 70 Israel: Diverticulitis Disease Market, by End-User, 2019-2032 (USD Billion)
  • Table 71 South Africa: Diverticulitis Disease Market, by Type, 2019-2032 (USD Billion)
  • Table 72 South Africa: Diverticulitis Disease Market, by Treatment, 2019-2032 (USD Billion)
  • Table 73 South Africa: Diverticulitis Disease Market, by End-User, 2019-2032 (USD Billion)
  • Table 74 Latin America: Diverticulitis Disease Market, by Type, 2019-2032 (USD Billion)
  • Table 75 Latin America: Diverticulitis Disease Market, by Treatment, 2019-2032 (USD Billion)
  • Table 76 Latin America: Diverticulitis Disease Market, by End-User, 2019-2032 (USD Billion)
  • Table 77 Mexico: Diverticulitis Disease Market, by Type, 2019-2032 (USD Billion)
  • Table 78 Mexico: Diverticulitis Disease Market, by Treatment, 2019-2032 (USD Billion)
  • Table 79 Mexico: Diverticulitis Disease Market, by End-User, 2019-2032 (USD Billion)
  • Table 80 Brazil: Diverticulitis Disease Market, by Type, 2019-2032 (USD Billion)
  • Table 81 Brazil: Diverticulitis Disease Market, by Treatment, 2019-2032 (USD Billion)
  • Table 82 Brazil: Diverticulitis Disease Market, by End-User, 2019-2032 (USD Billion)
  • Table 83 Argentina: Diverticulitis Disease Market, by Type, 2019-2032 (USD Billion)
  • Table 84 Argentina: Diverticulitis Disease Market, by Treatment, 2019-2032 (USD Billion)
  • Table 85 Argentina: Diverticulitis Disease Market, by End-User, 2019-2032 (USD Billion)

List of Figures

  • Figure 1. Global Diverticulitis Disease Market, 2019-2032 (USD Billion)
  • Figure 2. Integrated Ecosystem
  • Figure 3. Research Methodology: Top-Down & Bottom-Up Approach
  • Figure 4. Market by Geography
  • Figure 5. Porter's Five Forces
  • Figure 6. Market by Treatment
  • Figure 7. Global Diverticulitis Disease Market, by Treatment, 2021 & 2030 (USD Billion)
  • Figure 8. Market by Type
  • Figure 9. Global Diverticulitis Disease Market, by Type, 2021 & 2030 (USD Billion)
  • Figure 10. Market by End-User
  • Figure 11. Global Diverticulitis Disease Market, by End-User, 2021 & 2030 (USD Billion)
  • Figure 12. Diverticulitis Disease Market Assessment, By Geography, 2019-2032 (USD Billion)
  • Figure 13. Strategic Analysis - Diverticulitis Disease Market